Glucagon levels and counterregulation during the hyperinsulinemic hypoglycemic clamp test in subjects with insulin-treated type 2 diabetes
| Lixisenatide | Placebo | P value | |
|---|---|---|---|
| Glucagon level at 0 min (pmol/L) | 10.7 ± 1.3 | 9.8 ± 1.2 | 0.18 |
| Glucagon level at 60 min (pmol/L) | 4.5 ± 0.7 | 6.0 ± 0.8 | 0.005 |
| Glucagon level at 120 min (pmol/L) | 11.2 ± 1.7 | 16.1 ± 2.6 | 0.045 |
| ∆Glucagon at 3.5 mmol/L (60–120 min) (pmol/L) | 6.7 ± 1.6 | 10.1 ± 2.3 | 0.20 |
| Mean glucagon at 3.5 mmol/L (60–120 min) (pmol/L) | 8.1 ± 1.1 | 11.4 ± 1.6 | 0.008 |
| AUC glucagon at 3.5 mmol/L (60–120 min) (pmol/L · min) | 471 ± 63 | 668 ± 91 | 0.013 |
| Glucagon level at 180 min (pmol/L) | 21.7 ± 3.4 | 21.1 ± 3.0 | 0.827 |
| ∆Glucagon at 2.8 mmol/L (120–180 min) (pmol/L) | 10.5 ± 2.3 | 4.9 ± 2.3 | 0.042 |
| Mean glucagon at 2.8 mmol/L (min 120–180 min) (pmol/L) | 19.2 ± 2.9 | 20.7 ± 2.9 | 0.63 |
| AUC glucagon at 2.8 mmol/L (120–180 min) (pmol/L · min) | 988 ± 147 | 1,116 ± 152 | 0.36 |
| ∆Glucagon during whole clamp (60–180 min) (pmol/L) | 17.2 ± 3.0 | 15.0 ± 2.5 | 0.45 |
| AUC glucagon during whole clamp (60–180 min) (pmol/L · min) | 1,460 ± 208 | 1,782 ± 29 | 0.12 |
| Glucagon level at 240 min | 13.8 ± 1.9 | 23.8 ± 2.3 | <0.001 |
Data are reported as the mean ± SEM, unless otherwise indicated. ∆, change in level.